Results 21 to 30 of about 4,782 (272)

Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management

Journal of Allergy and Clinical Immunology: in Practice, 2022
Treatment guidelines recommend triple therapy for patients with asthma who remain uncontrolled on inhaled corticosteroid/long-acting β2-agonist therapy. Previously, triple therapy was only available via multiple inhalers. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) is approved as maintenance treatment for asthma; however ...
William W Busse, François Laliberté, Sean D MacKnight   +2 more
exaly   +3 more sources

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. [PDF]

Adv Ther, 2020
The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exacerbations compared with FF/VI or UMEC/VI in patients with ...
Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC, Lipson DA.   +14 more
europepmc   +7 more sources

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

BMC Health Services Research, 2022
Background The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations.
Emanuela Resta, Giulia Scioscia, Donato Lacedonia, Carla Maria Irene Quarato, Francesco Panza, Onofrio Resta, Giorgia Lepore, Enrico Buonamico, Valentina Di Lecce, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro, Noemi Rossi   +11 more
doaj   +6 more sources

Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review [PDF]

ERJ Open Research, 2022
Obstructive airway disease (OAD), which includes COPD and asthma, is the leading cause of morbidity and mortality in India. Long-acting bronchodilators (long-acting β2 agonists (LABAs) and/or long-acting muscarinic antagonists (LAMAs)) and inhaled ...
Raja Dhar, Deepak Talwar, Sundeep Salvi, B.V. Muralimohan, Sagar Panchal, Saiprasad Patil, Sagar Bhagat, Nishtha Khatri, Hanmant Barkate   +8 more
doaj   +2 more sources

Adherence to single inhaler triple therapy and digital inhalers in Chronic Obstructive Pulmonary Disease: a literature review and protocol for a randomized controlled trial (TRICOLON study) [PDF]

BMC Pulmonary Medicine
Background Medication non-adherence is a significant problem in patients with Chronic Obstructive Pulmonary Disease (COPD). Efforts to address this issue are receiving increased attention.
Liz J. A. Cuperus, Job van der Palen, Arnoud Aldenkamp, Astrid van Huisstede, Erik W. M. A. Bischoff, Job F. M. van Boven, Folkert Brijker, Stephan Dik, Jeroen A. J. M. van Excel, Martijn Goosens, Peter Th. W. van Hal, Jolanda C. Kuijvenhoven, Lisette I. Z. Kunz, Erwin C. Vasbinder, Huib A. M. Kerstjens, Johannes C. C. M. in ’t Veen, the TRICOLON study group   +16 more
doaj   +2 more sources

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses [PDF]

ERJ Open Research, 2018
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations.
David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson   +8 more
doaj   +5 more sources

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial. [PDF]

Int J Chron Obstruct Pulmon Dis, 2019
We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513).Baseline inputs and treatment effects from IMPACT were populated ...
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DM, Han MK, Lomas DA.   +11 more
europepmc   +6 more sources

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Pulmonary Therapy
Introduction Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β2-agonist; however, characterization of elderly
Russell A. Settipane, Guillaume Germain, Francois Laliberté, Malena Mahendran, Annalise Hilts, Mei Sheng Duh, Rosirene Paczkowski, Emmeline Burrows   +7 more
doaj   +2 more sources

Real-World Effectiveness of Single-Inhaler Triple Therapy for COPD: Impact of Diabetes Comorbidity

COPD
Background Type 2 diabetes is a frequent comorbidity in chronic obstructive pulmonary disease (COPD) patients, with the GOLD treatment recommendations asserting that the presence of diabetes be disregarded in the choice of treatment.Methods In a cohort ...
Sophia Eilat-Tsanani, Pierre Ernst, Samy Suissa   +2 more
doaj   +3 more sources

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Ruan Z, Wang C, Yuan S, Fan Y, Xu B, Cong X, Li D, Miao Q.   +7 more
europepmc   +2 more sources